Drug intelligence / Profile preview

MAC-3-190

Development stage: Preclinical
Modality: Small Molecules
Administration: Intraperitoneal, Intravenous

Overview

**MAC-3-190** is a small molecule inhibitor targeting neuronal nitric oxide synthase (nNOS). It has demonstrated activity as an anti-melanoma agent in preclinical studies, but shows limited efficacy as a monotherapy in vivo unless co-administered with a melanoma-targeted delivery peptide (KK-11), which enhances its tumor accumulation and antitumor effect. The drug is designed to inhibit nNOS as a targeted therapy, aiming to suppress melanoma cell proliferation. Development is focused on improving efficacy and delivery via conjugation or co-administration with cell-targeting ligands for selective melanoma treatment[1][4].

Brand names: MAC-3-190MAC3-190MAC 3-190
Other names: MAC-3-190MAC3-190MAC 3-190

Targets

NOS1 (nNOS)

Beyond the preview

Go deeper on MAC-3-190.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAC-3-190.

Explore the full profile